Background/Objectives: Glioblastoma (GBM) is a lethal form of primary brain tumor. There has been minimal improvement in overall GBM survival in recent years. To increase survival in patients with GBM, it is important to study novel GBM molecular antigens to form the basis of better diagnostics, prognostic measures, and therapeutic advancements. Our goal is to find more robust GBM-specific antigenic biomarkers to eventually improve GBM outcomes. Here, we initiated an investigation into cell-surface PCNA (csPCNA), a potential GBM biomarker and antigenic target.Methods: We utilized flow cytometry, imaging flow cytometry, and cell-surface Western blot to identify the expression of csPCNA on GBM cell lines (LN-229, LN-18) and a primary patient-derived tumor specimen. We then employed flow cytometry to study the associative co-expression of csPCNA with other biomarkers of GBM stem cells (CD44, CD49f) and GBM immunosuppression (PD-L1, TGFβRII).Results: We elucidated that LN-229, LN-18, and the primary GBM patient cells express csPCNA. We found that csPCNA is co-expressed with CD44, CD49f, PD-L1, and TGFβRII on the primary patient-derived GBM specimen.Conclusions: Our findings that csPCNA is expressed in GBM and is co-expressed with stem cell and immunosuppressive biomarkers indicate that csPCNA may be a potentially useful clinical–pathological biomarker for GBM stemness and immunosuppression.
背景/目的：胶质母细胞瘤（GBM）是一种致命性的原发性脑肿瘤。近年来，GBM患者的总体生存率改善甚微。为提高GBM患者的生存率，研究新型GBM分子抗原以构建更优诊断、预后评估及治疗进展的基础至关重要。本研究旨在寻找更具特异性的GBM抗原生物标志物，以期最终改善GBM临床结局。本文针对细胞表面增殖细胞核抗原（csPCNA）——一种潜在的GBM生物标志物与抗原靶点——展开了初步研究。 方法：我们采用流式细胞术、成像流式细胞术及细胞表面蛋白质印迹技术，检测了GBM细胞系（LN-229、LN-18）及原代患者来源肿瘤样本中csPCNA的表达情况。随后通过流式细胞术分析了csPCNA与GBM干细胞标志物（CD44、CD49f）及免疫抑制标志物（PD-L1、TGFβRII）的共表达关系。 结果：研究证实LN-229、LN-18细胞系及原代GBM患者细胞均表达csPCNA。在原代患者来源GBM样本中，csPCNA与CD44、CD49f、PD-L1及TGFβRII存在共表达现象。 结论：csPCNA在GBM中的表达及其与干细胞标志物、免疫抑制标志物的共表达特征表明，csPCNA可能成为评估GBM干细胞特性与免疫抑制状态的潜在临床病理学生物标志物。
Cell-Surface PCNA Is Co-Expressed with Biomarkers of Stemness and Immunosuppression in Glioblastoma
肿瘤(癌症)患者之家